Zhang Juan, Sang Jingjing, Jiang Yanyan, Zheng Yi, Zhang Jing, Liu Xuesen, Qiu Huafeng, Zhao Kaijian, Sun Hongmei, Yang Yang, Chen Hao, Yang Lei
Department of Scientific Research Section, The First People's Hospital of Zhumadian, Affiliated Hospital of Huanghuai University, Zhumadian, China.
Institute of Monogenic Disease, School of Medicine, Huanghuai University, Zhumadian, China.
Front Endocrinol (Lausanne). 2025 Apr 30;16:1434745. doi: 10.3389/fendo.2025.1434745. eCollection 2025.
OBJECTIVE: To ascertain whether vascular complications and high lipoprotein (a) [Lp(a)] concentrations are related in individuals with early-onset type 2 diabetes mellitus (T2DM). METHODS: This observational cross-sectional study included 591 individuals with early-onset T2DM who were divided into four groups based on Lp(a) values which was measured using immunoturbidimetry and presented as mg/dL: high, >50; intermediate, 30≤Lp(a)<50; low, 10≤Lp(a)<30; and very low, <10. The relationship between the risk of vascular complications and Lp(a) level was examined using a logistic regression model. RESULTS: The median age of onset for individuals with early-onset T2DM (n=591) was 37 years, duration of diabetes was 12 years, and glycated hemoglobin (HbA1c) level was 8.8%. The median Lp(a) was 10.40 (4.80-21.80) mg/dL, and Lp(a) concentration did not correlate with age, sex, or glycemic control (>0.05). Individuals in the low Lp(a) (OR=2.12, 95% CI 1.17-3.84, <0.05), intermediate Lp(a) (OR=2.76, 95% CI 1.10-6.98, <0.05) and high Lp(a) (OR=4.79, 95% CI 2.03-11.31, <0.01) groups had an increased risk of coronary heart disease (CHD) compared with those in the very low Lp(a) group after adjustment. Nevertheless, among individuals with early-onset T2DM, there was no correlation between Lp(a) concentration and the risk of cerebrovascular disease (CVL) and microvascular complications (>0.05). CONCLUSIONS: In patients with early-onset T2DM, Lp(a) concentration was independently associated with CHD. Lp(a) testing is essential to determine who has a latent high risk of CHD among patients with early-onset T2DM.
Front Endocrinol (Lausanne). 2025-4-30
J Am Coll Cardiol. 2024-1-23
Lancet Diabetes Endocrinol. 2023-10
Invest Ophthalmol Vis Sci. 2023-5-1
Int J Biol Macromol. 2023-4-1